JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 26, 2006; DOI: 10.1124/jpet.105.098541


0022-3565/06/3172-850-857$20.00
JPET 317:850-857, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.098541v1
317/2/850    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, H.-J.
Right arrow Articles by DeVane, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, H.-J.
Right arrow Articles by DeVane, C. L.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana

Hao-Jie Zhu, Jun-Sheng Wang, John S. Markowitz, Jennifer L. Donovan, Bryan B. Gibson, Holly A. Gefroh, and C. Lindsay DeVane

Laboratory of Drug Disposition and Pharmacogenetics, Departments of Pharmaceutical Sciences (H.-J.Z., J.S.M.) and Psychiatry and Behavioral Sciences (J.-S.W., J.L.D., B.B.G., H.A.G., C.L.D.), Medical University of South Carolina, Charleston, South Carolina

The ATP-dependent drug efflux transporter P-glycoprotein (P-gp) plays a significant role in the absorption and disposition of many compounds. The purpose of this study was to investigate the possible interaction of P-gp with each of four major mari-juana constituents: {Delta}9-tetrahydrocannabinol (THC), 11-nor-{Delta}9-tetrahydrocannabinol-carboxylic acid (THC-COOH), cannabinol (CBN), and cannabidiol (CBD). The results of a P-gp ATPase activity screen showed that THC-COOH, CBN, THC, and CBD all stimulated P-gp ATPase activity with a Michaelis-Menten parameter (Vmax/Km) value of 1.3, 0.7, 0.1, and 0.05, respectively. Furthermore, CBD showed a concentration-dependent inhibitory effect on verapamil-stimulated ATPase activity with an IC50 value of 39.6 µM, whereas all other tested cannabinoids did not display appreciable inhibitory effects. Thus, the inhibitory effects of CBD on P-gp transport were further studied. At concentrations ranging from 5 to 100 µM, CBD robustly enhanced the intracellular accumulation of known P-gp substrates rhodamine 123 and doxorubicin in a concentration-dependent manner in Caco-2 and LLC-PK1/MDR1 cells. An IC50 value of 8.44 µM was obtained for inhibition of P-gp function in LLC-PK1/MDR1 cells as determined by flow cytometry using rhodamine 123 as a fluorescence probe. Following exposure to 30 µM CBD, the apparent permeability coefficient of rhodamine 123 across Caco-2 and rat brain microvessel endothelial cell monolayers was increased to 2.2- and 2.6-fold in the apical-to-basolateral direction but decreased to 0.69- and 0.47-fold in the basolateral-to-apical direction, respectively. These findings indicate that CBD significantly inhibits P-gp-mediated drug transport, suggesting CBD could potentially influence the absorption and disposition of other coadministered compounds that are P-gp substrates.


Received November 10, 2005; accepted January 25, 2006.

Address correspondence to: Dr. C. Lindsay DeVane, Laboratory of Drug Disposition and Pharmacogenetics, Medical University of South Carolina, 173 Ashley Ave., Rm 405B, Charleston, SC 29425. E-mail: devanel{at}musc.edu




This article has been cited by other articles:


Home page
The OncologistHome page
F. K. Engels, F. A. de Jong, A. Sparreboom, R. A. A. Mathot, W. J. Loos, J. J. E. M. Kitzen, P. de Bruijn, J. Verweij, and R. H. J. Mathijssen
Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel
Oncologist, March 1, 2007; 12(3): 291 - 300.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.